What did @melissahadleybarrett actually say?
Barrett set out to debunk three claims about Peyronie's disease. She said it affects "one in 10 men" in their lifetime, pushing back on the idea it's rare. She also argued that injury isn't the only cause, pointing to genetics, diabetes, hypertension, and connective tissue disorders. Finally, she challenged the notion that surgery is the only fix, noting that "quite a lot of different conservative options" exist. These are reasonable claims to make, and most of them hold up reasonably well under scrutiny.
Does the science back this up?
Mostly, yes, with some caveats worth knowing. The prevalence figure is the one that needs the most context. Studies suggest Peyronie's disease is genuinely underdiagnosed, and estimates vary widely.
A 2016 population-based study by Stuntz et al. published in PLOS ONE estimated prevalence at around 0.5% to 13% depending on methodology and age group, which is consistent with a rough "1 in 10" figure in older populations. A frequently cited estimate from Mulhall et al. (2004, Journal of Sexual Medicine) found prevalence of about 8.9% in men attending a urology clinic, which skews high. In general-population screening studies, the number is lower. So Barrett's figure isn't wrong, but it isn't a universal truth either.
On causes, the literature is clear that injury, genetics, and comorbidities like diabetes and hypertension are all recognized contributing factors. The connective tissue link is well established, particularly with Dupuytren's contracture. Bivalacqua et al. and other researchers have documented the fibrotic pathology in detail.
What did they get wrong (or right)?
The "1 in 10" statistic deserves more precision than it got. Barrett presents it as a flat lifetime figure, but the actual data is age-dependent. Prevalence rises sharply in men over 50 and is substantially lower in younger men. Quoting that number without the age caveat makes it sound more alarming and universal than the evidence supports. That's a meaningful omission, not a fabrication.
Everything else she said lands reasonably well. The multi-factorial cause framework is accurate. Genetics matter here: studies have found Peyronie's is more common in men with a family history and in those with HLA-associated connective tissue disorders. The diabetes and hypertension connections are supported by multiple studies, including Arafa et al. (2007, International Journal of Impotence Research).
Her point about non-surgical options is correct and genuinely useful. Intralesional collagenase injections (Xiaflex) received FDA approval specifically for Peyronie's disease in 2013. Oral pentoxifylline, vacuum erection devices, and traction therapy are also used in clinical practice. Saying surgery isn't the only path is accurate and probably reduces unnecessary anxiety for men watching this video.
What should you actually know?
Peyronie's disease is a fibrotic condition of the tunica albuginea, the sheath surrounding erectile tissue. It causes scar tissue, called a plaque, to form, which leads to penile curvature, pain during erections, and in some cases erectile dysfunction. It is not just a cosmetic issue, and the ED component is underappreciated.
The condition has an acute phase, typically the first 12 to 18 months, where the plaque is active and curvature may worsen, and a stable phase after that. Treatment decisions often depend on which phase a man is in. Conservative treatments are generally recommended during the acute phase; surgical correction is typically reserved for stable disease with significant curvature or functional impairment.
If you're seeing curvature develop, pain during erections, or a palpable lump along the shaft, see a urologist. A primary care doctor can refer you, and telehealth platforms can be an appropriate first step for initial assessment and referral coordination. Waiting and hoping it resolves is not always the wrong move, roughly 13% of cases do improve spontaneously, but active management options exist and are worth discussing.